Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent
P&T (Pharmacy & Therapeutics)
Publication Date / Copyright Date
Schizophrenia is a chronic mental illness known as one of the most complex and challenging psychiatric disorders to treat.1 It is a heterogeneous clinical syndrome involving a compilation of cognitive, behavioral, and emotional dysfunctions.2 The mainstay of treatment for schizophrenia is pharmacotherapy, and in many cases it is impossible to implement effective psychosocial rehabilitation without antipsychotic treatment.1 However, one of the difficulties in the treatment of schizophrenia is patient nonadherence to medication regimens, with the percentage of nonadherence reported as 40% to 60% to antipsychotics and 11% to 80% in patients with schizophrenia.3 Many consequences of poor compliance are known, including relapse, hospitalization, exacerbations, behavior harmful to one’s self or others, suicide, and overall negative impacts on patients, their families, and society as a whole.3–4 The most common cause of relapse is poor adherence, with relapse in first-episode patients increasing almost fivefold when antipsychotic drug treatment is discontinued.4–6
Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences
antipsychotics, Invega Trinza, psychiatry, schizophrenia
Daghistani, Noor and Rey, Jose A., "Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent" (2016). Faculty Articles. 332.